Srdan Verstovsek
University of Texas MD Anderson Cancer Center
1213 Papers
6.7K Citations
Srdan Verstovsek is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Myelofibrosis. The author has an hindex of 96, co-authored 1045 publications. Previous affiliations of Srdan Verstovsek include Baylor College of Medicine & First Faculty of Medicine, Charles University in Prague.
Chat about Author
Papers
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
Francis J. Giles,Alison Stopeck,Lewis R. Silverman,Jeffrey E. Lancet,Maureen Cooper,Alison L. Hannah,Julie M. Cherrington,Anne Marie O'Farrell,Helene A. Yuen,Sharianne G. Louie,Weiru Hong,Jorge E. Cortes,Srdan Verstovsek,Maher Albitar,Susan O'Brien,Hagop M. Kantarjian,Judith E. Karp +16 more
TL;DR: Single agent SU5416 had biologic and modest clinical activity in refractory AML/MDS and studies of other RTKI and/or other antiangiogenic approaches, with correlative studies to examine biologic effects, may be warranted in patients with AML or MDS.
219
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy
Apostolia Maria Tsimberidou,Hagop M. Kantarjian,Eli Estey,Jorge E. Cortes,Srdan Verstovsek,Stephan Faderl,Deborah A. Thomas,Guillermo Garcia-Manero,Alessandra Ferrajoli,John T. Manning,Michael J. Keating,Maher Albitar,Stephen J. O'Brien,Francis J. Giles +13 more
TL;DR: Novel therapies for patients with GS are required as the frequency, presenting characteristics, and survival in patients with nonleukemic GS are described by conducting a review of all untreated patients presenting to the MD Anderson Cancer Center between January 1990 and June 2002.
219
Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
Ayalew Tefferi,Srdan Verstovsek,Giovanni Barosi,Francesco Passamonti,Gail J. Roboz,Heinz Gisslinger,Ronald Paquette,Francisco Cervantes,Candido E. Rivera,H. Joachim Deeg,Juergen Thiele,Hans Michael Kvasnicka,James W. Vardiman,Yanming Zhang,B. Nebiyou Bekele,Ruben A. Mesa,Robert P. Gale,Hagop M. Kantarjian +17 more
TL;DR: Pomalidomide therapy at 0.5 or 2 mg/d with or without an abbreviated course of prednisone is well tolerated in patients with myelofibrosis and active in the treatment of anemia.
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.
Kate J. Newberry,Keyur P. Patel,Lucia Masarova,Rajyalakshmi Luthra,Taghi Manshouri,Elias Jabbour,Prithviraj Bose,Naval Daver,Jorge E. Cortes,Hagop M. Kantarjian,Srdan Verstovsek +10 more
TL;DR: Outcomes after ruxolitinib discontinuation in MF patients enrolled in a phase 1/2 study are described and it is suggested that clonal evolution or decreasing platelet counts while on ruxolinib therapy may be markers of poor prognosis.
208
Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center
Qi Liu,Luis Fayad,Fernando Cabanillas,Fredrick B. Hagemeister,Gregory D. Ayers,Mark A. Hess,Jorge E. Romaguera,M. Alma Rodriguez,Apostolia Maria Tsimberidou,Srdan Verstovsek,Anas Younes,Barbara Pro,Ming Sheng Lee,Ana Ayala,Peter McLaughlin +14 more
TL;DR: Evolving therapy, including the incorporation of biologic agents, has led to stepwise significant outcome improvements for patients with advanced-stage follicular lymphoma, and the apparent plateau in the FFS curve raises the issue of the potential curability of these patients.
207